{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:34:17Z","timestamp":1789122857738,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clbc.2021.12.009","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T12:13:08Z","timestamp":1640607188000},"page":"e576-e585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-7265","authenticated-orcid":false,"given":"Semir","family":"Vranic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Gatalica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2021.12.009_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2021.12.009_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2021.12.009_bib0003","volume":"2","author":"Board","year":"2019"},{"key":"10.1016\/j.clbc.2021.12.009_bib0004","first-page":"1393","article-title":"Apocrine carcinoma of the breast: a comprehensive review","volume":"28","author":"Vranic","year":"2013","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17305\/bjbms.2016.1811","article-title":"Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers","volume":"17","author":"Vranic","year":"2017","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0006","article-title":"Carcinoma with apocrine differentiation","volume":"2","author":"Provenzano","year":"2019"},{"key":"10.1016\/j.clbc.2021.12.009_bib0007","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2021.12.009_bib0008","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1038\/sj.onc.1209415","article-title":"An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen","volume":"25","author":"Doane","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2021.12.009_bib0009","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2021.12.009_bib0010","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr3421","article-title":"Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15","volume":"15","author":"Lehmann-Che","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41416-019-0420-y","article-title":"Molecular apocrine tumours in EORTC 10994\/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes","volume":"120","author":"Bonnefoi","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.04.002","article-title":"Androgen receptor in breast cancer: a wolf in sheep's clothing? A lesson from prostate cancer","volume":"60","author":"Salvi","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0013","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/cas.12121","article-title":"Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation","volume":"104","author":"McNamara","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/modpathol.2009.159","article-title":"Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation","volume":"23","author":"Niemeier","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdp510","article-title":"Expression of androgen receptors in primary breast cancer","volume":"21","author":"Park","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-019-1118-z","article-title":"Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98","volume":"21","author":"Kensler","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/molecules25020358","article-title":"Androgen receptor in breast cancer-clinical and preclinical research insights","volume":"25","author":"Anestis","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.clbc.2021.12.009_bib0018","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1200\/JCO.2013.49.8899","article-title":"Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literature","volume":"34","author":"Arce-Salinas","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0019","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2020.11.008","article-title":"Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer","volume":"144","author":"Boers","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2019-0564","article-title":"Bicalutamide plus aromatase inhibitor in patients with estrogen receptor-positive\/androgen receptor-positive advanced breast cancer","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2021.12.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/11782234211002491","article-title":"Emerging therapeutic drugs in metastatic triple-negative breast cancer","volume":"15","author":"Cipriano","year":"2021","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.clbc.2021.12.009_bib0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1054\/brst.1999.0070","article-title":"Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety","volume":"9","author":"Kasami","year":"2000","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2021.12.009_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3233\/CBM-150525","article-title":"The polymorphism of CAG repeats in the androgen receptor gene and breast cancer mortality","volume":"15","author":"Lee","year":"2015","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.clbc.2021.12.009_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00428-021-03028-2","article-title":"Chromosome X aneusomy and androgen receptor gene copy number aberrations in apocrine carcinoma of the breast","volume":"479","author":"Cremonini","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clbc.2021.12.009_bib0026","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2021.12.009_bib0027","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0028","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2021.12.009_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2021.12.009_bib0030","doi-asserted-by":"crossref","first-page":"44728","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2021.12.009_bib0031","article-title":"Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations","author":"Ferguson","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0032","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1172\/JCI76412","article-title":"Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer","volume":"124","author":"Qin","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2021.12.009_bib0033","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0034","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.humpath.2021.07.005","article-title":"alpha-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation","volume":"116","author":"Nakamura","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-019-0871-8","article-title":"Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?","volume":"14","author":"Alston","year":"2019","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0036","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jnci\/djq526","article-title":"Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies","volume":"103","author":"Yang","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2021.12.009_bib0037","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/ijms21010053","article-title":"Role of claudin proteins in regulating cancer stem cells and chemoresistance-potential implication in disease prognosis and therapy","volume":"21","author":"Gowrikumar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0038","doi-asserted-by":"crossref","first-page":"18148","DOI":"10.3390\/ijms140918148","article-title":"Emerging roles of claudins in human cancer","volume":"14","author":"Kwon","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0039","doi-asserted-by":"crossref","first-page":"R296","DOI":"10.1186\/bcr983","article-title":"Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study","volume":"7","author":"Tokes","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s12253-019-00662-9","article-title":"All benign and malignant apocrine breast lesions over-express claudin 1 and 3 and are negative for claudin 4","volume":"26","author":"Shousha","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0041","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.3390\/ijms20194940","article-title":"The regulatory role of MicroRNAs in breast cancer","volume":"20","author":"Loh","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0042","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1038\/s41598-021-84350-2","article-title":"Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer","volume":"11","author":"Koleckova","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2021.12.009_bib0043","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clbc.2020.02.008","article-title":"Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers","volume":"20","author":"Vranic","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0044","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI39675","article-title":"EMT: when epithelial cells decide to become mesenchymal-like cells","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2021.12.009_bib0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2021.12.009_bib0046","year":"2021","journal-title":"Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0047","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clbc.2021.04.011","article-title":"Impact of Anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase Ib study","volume":"21","author":"Hamilton","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0048","unstructured":"FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. 2021; https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer."},{"key":"10.1016\/j.clbc.2021.12.009_bib0049","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/PAS.0000000000000780","article-title":"PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors","volume":"41","author":"Dill","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0050","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","article-title":"Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas","volume":"33","author":"Sun","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0051","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/cancers13102328","article-title":"CXCR2 levels correlate with immune infiltration and a better prognosis of triple-negative breast cancers","volume":"13","author":"Boissiere-Michot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2021.12.009_bib0052","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/PAS.0000000000001653","article-title":"MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1\/PD-L1 checkpoint inhibitors","volume":"45","author":"Dusenbery","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0053","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0054","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clbc.2021.12.009_bib0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5644\/ama2006-124.325","article-title":"The role of pathology in the era of personalized (precision) medicine: a brief review","volume":"50","author":"Vranic","year":"2021","journal-title":"Acta Med Acad"},{"issue":"8 Supplement","key":"10.1016\/j.clbc.2021.12.009_bib0056","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/1538-7445.AM2013-2013","article-title":"Abstract 2013: Comprehensive genetic characterization of apocrine lesions of the breast","volume":"73","author":"Costa","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0057","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.humpath.2015.05.017","article-title":"Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast","volume":"46","author":"Vranic","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0058","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0059","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0060","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fonc.2019.00452","article-title":"Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease","volume":"9","author":"Dieci","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0061","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-020-05727-x","article-title":"A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns","volume":"182","author":"Tzikas","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2021.12.009_bib0062","first-page":"S55","article-title":"HER2-positive apocrine carcinoma of the breast: a population-based analysis of incidence, treatment, and outcome","volume":"477","author":"Skenderi","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clbc.2021.12.009_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153677","article-title":"Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma","volume":"228","author":"Zhao","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clbc.2021.12.009_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2021.12.009_bib0065","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/tbj.13140","article-title":"A clinicopathologic study of invasive apocrine carcinoma of the breast: a single-center experience","volume":"24","author":"Imamovic","year":"2018","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2021.12.009_bib0066","doi-asserted-by":"crossref","first-page":"26406","DOI":"10.18632\/oncotarget.25413","article-title":"Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy","volume":"9","author":"Santonja","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2021.12.009_bib0067","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","article-title":"Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification","volume":"24","author":"Echavarria","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0068","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-021-06259-8","article-title":"Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review","volume":"187","author":"Trapani","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2021.12.009_bib0069","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000509638","article-title":"Predictors of response and survival outcomes of triple negative breast cancer receiving neoadjuvant chemotherapy","volume":"65","author":"Zhu","year":"2020","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clbc.2021.12.009_bib0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.31557\/APJCP.2020.21.2.563","article-title":"Neoadjuvant chemotherapy in triple negative breast cancer: correlation between androgen receptor expression and pathological response","volume":"21","author":"Mohammed","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clbc.2021.12.009_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.01.016","article-title":"The importance of EGFR as a biomarker in molecular apocrine breast cancer","volume":"77","author":"Liu","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0072","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-018-0762-y","article-title":"Androgen receptor and heat shock protein 27 co-regulate the malignant potential of molecular apocrine breast cancer","volume":"37","author":"Liu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.12.009_bib0073","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/cancers11081195","article-title":"Targeting heat shock protein 27 in cancer: a druggable target for cancer treatment?","volume":"11","author":"Choi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2021.12.009_bib0074","first-page":"1910","article-title":"Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer","volume":"25","author":"Di Leone","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clbc.2021.12.009_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/PAI.0000000000000897","article-title":"Molecular subtyping of triple negative breast cancer by surrogate immunohistochemistry markers","volume":"29","author":"Kumar","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0076","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1245\/s10434-021-10518-9","article-title":"Apocrine breast cancer: unique features of a predominantly triple-negative breast cancer","volume":"28","author":"Saridakis","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0077","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2021.01.005","article-title":"Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women","volume":"111","author":"Honma","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0078","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12885-020-06998-9","article-title":"Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis","volume":"20","author":"Sanges","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0079","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-020-05861-6","article-title":"Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type","volume":"184","author":"Kim","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2021.12.009_bib0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2020.09.006","article-title":"Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysis","volume":"54","author":"Han","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2021.12.009_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2019.100501","article-title":"The role of histopathologic testing on apocrine carcinoma of the breast","volume":"44","author":"Ilhan","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0082","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820943246","article-title":"Avoidance and period-shortening of neoadjuvant chemotherapy against triple-negative breast cancer in stages I and II: importance of Ki-67 labeling index and the recognition of apocrine-type lesions","volume":"19","author":"Kubouchi","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clbc.2021.12.009_bib0083","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5114\/pjp.2020.97018","article-title":"High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma","volume":"71","author":"Wysocka","year":"2020","journal-title":"Pol J Pathol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0084","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejso.2017.11.027","article-title":"Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis","volume":"44","author":"Zhao","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jso.26129","article-title":"Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers","volume":"122","author":"Arciero","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2021.12.009_bib0086","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2020.07.003","article-title":"Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy","volume":"53","author":"Montagna","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2021.12.009_bib0087","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/cam4.2634","article-title":"Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2021.12.009_bib0088","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1016\/j.clbc.2018.02.012","article-title":"Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a case-control study","volume":"18","author":"Meattini","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0089","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197827","article-title":"Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features","volume":"13","author":"Astvatsaturyan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2021.12.009_bib0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7150\/jca.22280","article-title":"The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer","volume":"9","author":"Liao","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.clbc.2021.12.009_bib0091","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2018.04.011","article-title":"Histologic heterogeneity of triple negative breast cancer: a national cancer centre database analysis","volume":"98","author":"Mills","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921003700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921003700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:23:37Z","timestamp":1761513817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820921003700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1526820921003700"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2021.12.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2021.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}